West Tower Group’s AbbVie ABBV Stock Holding History

West Tower Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-804	Closed	-$108K	–	588
2023 Q2	$108K	Buy	+804	New	+$118K	0.08%	97

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

West Tower Group's ABBV Position: Q3 2023 in Review

West Tower Group sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 804 shares — an estimated $108K sold.

West Tower Group first reported a position in ABBV in Q2 2023 and held it in 1 quarter. The position peaked at $108K in Q2 2023. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

West Tower Group reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
West Tower Group sold 804 AbbVie shares in Q3 2023, an estimated $108K.
West Tower Group first reported a position in AbbVie in Q2 2023 and held it in 1 quarter.
West Tower Group's AbbVie position peaked at $108K in Q2 2023.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on West Tower Group's 13F filing for Q3 2023, filed 14 Nov 2023.